$PVCT
PROVECTUS BIOPHARMACEUTICALS, INC.

2017 Q2 Form 10-Q Financial Statement

#000119312517165654 Filed on May 10, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2017 Q1 2016 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $920.0K $2.540M $3.510M
YoY Change -69.74% -58.36% -39.69%
% of Gross Profit
Research & Development $2.200M $1.854M $1.330M
YoY Change 9.73% -23.02% -63.76%
% of Gross Profit
Depreciation & Amortization $180.0K $2.631K $170.0K
YoY Change 0.0% -24.74% 0.0%
% of Gross Profit
Operating Expenses $3.300M $1.854M $5.183M
YoY Change -34.59% -78.21% -46.36%
Operating Profit -$4.398M
YoY Change -48.3%
Interest Expense $10.00K $10.00K $180.0K
YoY Change 1700.0%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00 $182.0K
YoY Change -100.0% -100.0% 1554.55%
Pretax Income -$3.290M -$4.390M -$5.000M
YoY Change -34.72% -48.41% -48.19%
Income Tax
% Of Pretax Income
Net Earnings -$3.290M -$4.389M -$5.001M
YoY Change -34.77% -48.4% -48.19%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$8.883K -$12.02K -$16.99K
COMMON SHARES
Basic Shares Outstanding 370.4M shares 364.8M shares 243.9M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q2 2017 Q1 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.130M $440.0K $1.170M
YoY Change -76.89% -95.49% -91.75%
Cash & Equivalents $1.130M $437.0K $1.166M
Short-Term Investments
Other Short-Term Assets $250.0K $250.5K $360.6K
YoY Change -21.03% -25.64% 775.32%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.470M $887.5K $1.826M
YoY Change -72.82% -91.51% -87.59%
LONG-TERM ASSETS
Property, Plant & Equipment $60.00K $69.40K $72.03K
YoY Change -23.23% -15.0% -15.4%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change -100.0%
Total Long-Term Assets $3.460M $3.623M $3.785M
YoY Change -36.17% -34.97% -33.83%
TOTAL ASSETS
Total Short-Term Assets $1.470M $887.5K $1.826M
Total Long-Term Assets $3.460M $3.623M $3.785M
Total Assets $4.930M $4.510M $5.611M
YoY Change -54.47% -71.84% -72.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.270M $2.770M $1.920M
YoY Change 324.68% 97.86% 1.59%
Accrued Expenses $320.0K $160.0K $220.0K
YoY Change -65.22% -63.64% -90.18%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $2.500M $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.590M $5.431M $2.142M
YoY Change 112.59% 196.01% -48.05%
LONG-TERM LIABILITIES
Long-Term Debt $5.550M $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $5.550M $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.590M $5.431M $2.142M
Total Long-Term Liabilities $5.550M $0.00 $0.00
Total Liabilities $9.140M $5.430M $2.140M
YoY Change 440.83% 196.72% -48.09%
SHAREHOLDERS EQUITY
Retained Earnings -$209.6M -$205.2M
YoY Change 10.73% 13.51%
Common Stock $370.4K $364.8K
YoY Change 74.02% 77.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.220M -$920.3K $3.469M
YoY Change
Total Liabilities & Shareholders Equity $4.930M $4.510M $5.611M
YoY Change -54.47% -71.84% -72.55%

Cashflow Statement

Concept 2017 Q2 2017 Q1 2016 Q4
OPERATING ACTIVITIES
Net Income -$3.290M -$4.389M -$5.001M
YoY Change -34.77% -48.4% -48.19%
Depreciation, Depletion And Amortization $180.0K $2.631K $170.0K
YoY Change 0.0% -24.74% 0.0%
Cash From Operating Activities -$2.360M -$3.230M -$4.020M
YoY Change -51.54% -59.88% -18.95%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.050M 2.500M 0.000
YoY Change -31.32% -100.0%
NET CHANGE
Cash From Operating Activities -2.360M -3.230M -4.020M
Cash From Investing Activities 0.000
Cash From Financing Activities 3.050M 2.500M 0.000
Net Change In Cash 690.0K -730.0K -4.020M
YoY Change -114.17% -83.45% -14.47%
FREE CASH FLOW
Cash From Operating Activities -$2.360M -$3.230M -$4.020M
Capital Expenditures $0.00
Free Cash Flow -$4.020M
YoY Change -18.95%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q4 pvct Class Of Warrant Or Right Cash Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightCashExercisePriceOfWarrantsOrRights
0.85
CY2016Q4 us-gaap Loss Contingency Receivable
LossContingencyReceivable
2240000
CY2017Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
370354643 shares
CY2013Q2 us-gaap Litigation Reserve
LitigationReserve
100000
CY2014Q2 us-gaap Loss Contingency Receivable
LossContingencyReceivable
2240000
CY2014Q2 pvct Reimbursement Receivable Percentage
ReimbursementReceivablePercentage
0.25 pure
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9760997
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
466772
CY2017Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
370354643 shares
CY2017Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
370354643 shares
CY2017Q1 us-gaap Assets
Assets
4510401
CY2017Q1 us-gaap Assets Current
AssetsCurrent
887467
CY2017Q1 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
2500000
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
436952
CY2017Q1 us-gaap Common Stock Value
CommonStockValue
370355
CY2017Q1 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
2770860
CY2017Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
208322249
CY2017Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2017Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
9641758
CY2017Q1 us-gaap Loss Contingency Receivable Current
LossContingencyReceivableCurrent
200000
CY2017Q1 us-gaap Loss Contingency Receivable Noncurrent
LossContingencyReceivableNoncurrent
1024345
CY2017Q1 us-gaap Other Assets Current
OtherAssetsCurrent
250515
CY2017Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
100 shares
CY2017Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4510401
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8052945
CY2017Q1 pvct Litigation Settlement Remaining Reserve
LitigationSettlementRemainingReserve
1549043
CY2017Q1 pvct Litigation Settlement Remaining Balance Due
LitigationSettlementRemainingBalanceDue
1224345
CY2017Q1 pvct Long Term Receivable Reimbursable Legal Fees
LongTermReceivableReimbursableLegalFees
455500
CY2017Q1 pvct Stockholders Equity Listing Requirement
StockholdersEquityListingRequirement
6000000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14178902
CY2017Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2073687
CY2017Q1 us-gaap Liabilities Current
LiabilitiesCurrent
5430715
CY2017Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
159855
CY2017Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
69402
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
-920314
CY2017Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-209612918
CY2017Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
100 shares
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-728786
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
464140
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
364773297 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
364773297 shares
CY2016Q4 us-gaap Assets
Assets
5611010
CY2016Q4 us-gaap Assets Current
AssetsCurrent
1826300
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1165738
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
364773
CY2016Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1919870
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
208327822
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2016Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
9473978
CY2016Q4 us-gaap Loss Contingency Receivable Current
LossContingencyReceivableCurrent
300000
CY2016Q4 us-gaap Loss Contingency Receivable Noncurrent
LossContingencyReceivableNoncurrent
1015710
CY2016Q4 us-gaap Other Assets Current
OtherAssetsCurrent
360562
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
8600 shares
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5611010
CY2016Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2241467
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2141826
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
221956
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
9
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
72033
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
3469184
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-205223420
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
8600 shares
CY2016Q4 pvct Long Term Receivable Reimbursable Legal Fees
LongTermReceivableReimbursableLegalFees
455500
CY2014Q2 us-gaap Loss Contingency Damages Paid Value
LossContingencyDamagesPaidValue
1120000
CY2014Q2 pvct Future Payments Ratio Of Contingent Consideration
FuturePaymentsRatioOfContingentConsideration
2 pure
CY2014Q2 pvct Annual Cash Bonus Percentage
AnnualCashBonusPercentage
0.70 pure
CY2014Q3 pvct Attorneys Fees Awarded By Court In Legal Settlement
AttorneysFeesAwardedByCourtInLegalSettlement
911000
CY2014Q4 pvct Share Based Compensation Arrangement By Share Based Payment Award Options Settlements In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSettlementsInPeriod
2800000 shares
CY2016 pvct Reserve For Uncollectibility Of Settlement Receivable
ReserveForUncollectibilityOfSettlementReceivable
1549043
CY2016 pvct Reserve For Uncollectibility Of Legal Fees Receivable
ReserveForUncollectibilityOfLegalFeesReceivable
455500
CY2017Q1 dei Entity Registrant Name
EntityRegistrantName
PROVECTUS BIOPHARMACEUTICALS, INC.
CY2017Q1 us-gaap Dividends Preferred Stock Paidinkind
DividendsPreferredStockPaidinkind
14007
CY2017Q1 dei Document Type
DocumentType
10-Q
CY2017Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000315545
CY2017Q1 dei Document Period End Date
DocumentPeriodEndDate
2017-03-31
CY2017Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-110047
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-4389498
CY2017Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-91365
CY2017Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4403505
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3228786
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2407984
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2017Q1 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
5582
CY2017Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017Q1 dei Amendment Flag
AmendmentFlag
false
CY2017Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2544600
CY2017Q1 us-gaap Depreciation
Depreciation
2631
CY2017Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2017Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2017Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
167780
CY2017Q1 us-gaap Interest Paid
InterestPaid
0
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-62101
CY2017Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
850990
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4398173
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2500000
CY2017Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2017Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
8675
CY2017Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
2500000
CY2017Q1 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> <b>1. Business Organization, Nature of Operations and Basis of Presentation</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> Provectus Biopharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, &#x201C;Provectus&#x201D; or the &#x201C;Company&#x201D;), is a biopharmaceutical company that is focusing on developing minimally invasive products for the treatment of psoriasis and other topical diseases, and certain forms of cancer including melanoma, breast cancer, and cancers of the liver. To date, the Company has not generated any revenues from planned principal operations. The Company&#x2019;s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company&#x2019;s prescription drug candidates, or sell or license the Company&#x2019;s&#xA0;<font style="WHITE-SPACE: nowrap"><font style="WHITE-SPACE: nowrap">over-the-counter</font></font>&#xA0;(&#x201C;OTC&#x201D;) products or&#xA0;<font style="WHITE-SPACE: nowrap">non-core</font>&#xA0;technologies.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial"> The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201C;GAAP&#x201D;) for interim financial information pursuant to&#xA0;<font style="WHITE-SPACE: nowrap">Regulation&#xA0;S-X.</font>&#xA0;Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be reviewed in conjunction with the Company&#x2019;s audited consolidated financial statements included in Form&#xA0;<font style="WHITE-SPACE: nowrap">10-K</font>&#xA0;for the year ended December&#xA0;31, 2016 filed with the U.S. Securities and Exchange Commission (&#x201C;SEC&#x201D;) on March&#xA0;31, 2017. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March&#xA0;31, 2017 are not necessarily indicative of the results that may be expected for the year ending December&#xA0;31, 2017.</p> </div>
CY2016Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8506303
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8507216
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
3635040
CY2016Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2016Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
913
CY2017Q1 us-gaap Stock Issued During Period Shares Conversion Of Units
StockIssuedDuringPeriodSharesConversionOfUnits
1594670 shares
CY2017Q1 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
3986676 shares
CY2017Q1 dei Trading Symbol
TradingSymbol
PVCT
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1853573
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
365207402 shares
CY2017Q1 pvct Litigation Settlement Present Value Of Discount Remaining
LitigationSettlementPresentValueOfDiscountRemaining
57623
CY2017Q1 pvct Litigation Settlement Payment Description
LitigationSettlementPaymentDescription
The remaining cash settlement amounts will continue to be repaid to the Company over the next three years with the final payment to be received by October 3, 2019.
CY2017Q1 pvct Issuance Inkind Of Preferred Stock Dividends
IssuanceInkindOfPreferredStockDividends
14007
CY2017Q1 pvct Reserve For Uncollectibility Of Settlement Receivable
ReserveForUncollectibilityOfSettlementReceivable
1549043
CY2017Q1 pvct Reserve For Uncollectibility Of Legal Fees Receivable
ReserveForUncollectibilityOfLegalFeesReceivable
455500
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4417905
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6099232
CY2016Q1 us-gaap Depreciation
Depreciation
3496
CY2016Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
167780
CY2016Q1 us-gaap Interest Paid
InterestPaid
0
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
51069
CY2016Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-489304
CY2016Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
295699
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-8506303
CY2016Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-127446
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
205278509 shares
CY2016Q1 pvct Issuance Of Stock For Services
IssuanceOfStockForServices
20163
CY2016Q1 pvct Increase Decrease In Accrued Settlement Expenses
IncreaseDecreaseInAccruedSettlementExpenses
-1850000
CY2016Q1 pvct Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
3635040
CY2016Q1 pvct Warrant Incentive Expense
WarrantIncentiveExpense
2718407

Files In Submission

Name View Source Status
0001193125-17-165654-index-headers.html Edgar Link pending
0001193125-17-165654-index.html Edgar Link pending
0001193125-17-165654.txt Edgar Link pending
0001193125-17-165654-xbrl.zip Edgar Link pending
d373832d10q.htm Edgar Link pending
d373832dex102.htm Edgar Link pending
d373832dex311.htm Edgar Link pending
d373832dex312.htm Edgar Link pending
d373832dex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
pvct-20170331.xml Edgar Link completed
pvct-20170331.xsd Edgar Link pending
pvct-20170331_cal.xml Edgar Link unprocessable
pvct-20170331_def.xml Edgar Link unprocessable
pvct-20170331_lab.xml Edgar Link unprocessable
pvct-20170331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending